Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement

Creative Commons License

Anagnostis P., Paschou S. A. , Mintziori G., Ceausu I., Depypere H., Lambrinoudaki I., et al.

MATURITAS, cilt.101, ss.23-30, 2017 (SCI İndekslerine Giren Dergi)


Background: Bisphosphonates and denosumab are used extensively in the treatment of postmenopausal osteoporosis. Despite their proven efficacy in the reduction of vertebral and non-vertebral fractures, their optimal duration of use has not been determined. The occurrence of adverse effects, such as osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF), has raised the issue of bisphosphonate or denosumab discontinuation ("drug holiday") after a certain treatment period.